IN2014MN01937A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01937A IN2014MN01937A IN1937MUN2014A IN2014MN01937A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A IN 1937MUN2014 A IN1937MUN2014 A IN 1937MUN2014A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A
- Authority
- IN
- India
- Prior art keywords
- subject
- metabolic syndrome
- diabetes mellitus
- risk
- level
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 2
- 108010054321 proneurotensin Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261608350P | 2012-03-08 | 2012-03-08 | |
EP12158680 | 2012-03-08 | ||
EP12165062 | 2012-04-20 | ||
PCT/EP2013/054801 WO2013132090A1 (en) | 2012-03-08 | 2013-03-08 | A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01937A true IN2014MN01937A (tr) | 2015-07-10 |
Family
ID=49115970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1937MUN2014 IN2014MN01937A (tr) | 2012-03-08 | 2013-03-08 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10520512B2 (tr) |
EP (1) | EP2823316B1 (tr) |
JP (1) | JP6262669B2 (tr) |
CN (1) | CN103308670B (tr) |
ES (1) | ES2684512T3 (tr) |
IN (1) | IN2014MN01937A (tr) |
RU (1) | RU2685713C2 (tr) |
TR (1) | TR201811201T4 (tr) |
WO (1) | WO2013132090A1 (tr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103308689B (zh) * | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
US20160097781A1 (en) * | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
EP3262421B1 (en) * | 2015-02-27 | 2020-02-26 | SphingoTec GmbH | A method for predicting the risk of obesity in a subject |
US10473670B2 (en) | 2016-02-25 | 2019-11-12 | University Of Kentucky Research Foundation | Method of predicting obesity comprising measuring neurotensin |
WO2022203533A1 (ru) * | 2021-03-25 | 2022-09-29 | Владимир Валерьевич ВОЛОБУЕВ | Способ оценки предрасположенности к различным формам сахарного диабета 2го типа |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8709871D0 (en) * | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
US5430047A (en) * | 1994-04-07 | 1995-07-04 | Warner-Lambert Company | Neurotensin antagonists |
US5968899A (en) * | 1994-06-03 | 1999-10-19 | Tsumura & Co. | Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption |
NZ506839A (en) * | 1998-03-09 | 2003-05-30 | Zealand Pharma As | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
US6248527B1 (en) * | 1998-10-21 | 2001-06-19 | Millennium Pharmaceuticals, Inc. | Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
JP4399254B2 (ja) * | 2001-06-20 | 2010-01-13 | キッセイ薬品工業株式会社 | 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体 |
WO2003020746A1 (en) | 2001-08-30 | 2003-03-13 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
ES2559927T3 (es) | 2002-06-07 | 2016-02-16 | Dyax Corp. | Prevención y reducción de pérdida de sangre y respuesta inflamatoria |
EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
CA2580881A1 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag | Use of microproteins as tryptase inhibitors |
DE102005003687A1 (de) * | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
CN101166981A (zh) * | 2005-04-11 | 2008-04-23 | 阿斯利康(瑞典)有限公司 | 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒 |
US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
WO2009077175A1 (en) | 2007-12-19 | 2009-06-25 | Affibody Ab | Polypeptide derived from protein a and able to bind pdgf |
JP5954990B2 (ja) | 2008-11-03 | 2016-07-20 | モレキュラー・パートナーズ・アーゲーMolecular Partners Ag | Vegf−aレセプター相互作用を阻害する結合タンパク質 |
EP2370471B1 (en) * | 2008-12-05 | 2017-02-22 | Angiochem Inc. | Neurotensin conjugate and uses thereof |
WO2010079158A1 (en) | 2009-01-07 | 2010-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment, the prognostic assessment and the detection of breast cancer |
EP2470556B1 (en) | 2009-08-27 | 2018-05-30 | Covagen AG | Il-17 binding compounds and medical uses thereof |
JP2013509588A (ja) * | 2009-10-29 | 2013-03-14 | テシス バイオサイエンス, インコーポレイテッド | 2型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー |
CA2778871C (en) | 2009-12-14 | 2017-08-01 | Scil Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
UA58612U (uk) * | 2010-06-04 | 2011-04-26 | Высшее Государственное Учебное Заведение «Украинская Медицинская Стоматологическая Академия» | Спосіб діагностики інсулінорезистентності у хворих на метаболічний синдром та цукровий діабет 2 типу |
JP5902679B2 (ja) | 2010-06-08 | 2016-04-13 | ピエリス アーゲーPieris Ag | IL−4Rαに結合する涙液リポカリンムテイン |
EP3262421B1 (en) * | 2015-02-27 | 2020-02-26 | SphingoTec GmbH | A method for predicting the risk of obesity in a subject |
-
2012
- 2012-10-08 CN CN201210509621.3A patent/CN103308670B/zh active Active
-
2013
- 2013-03-08 EP EP13708803.5A patent/EP2823316B1/en active Active
- 2013-03-08 IN IN1937MUN2014 patent/IN2014MN01937A/en unknown
- 2013-03-08 ES ES13708803.5T patent/ES2684512T3/es active Active
- 2013-03-08 RU RU2014140427A patent/RU2685713C2/ru active
- 2013-03-08 WO PCT/EP2013/054801 patent/WO2013132090A1/en active Application Filing
- 2013-03-08 JP JP2014560405A patent/JP6262669B2/ja active Active
- 2013-03-08 TR TR2018/11201T patent/TR201811201T4/tr unknown
- 2013-03-08 US US14/383,422 patent/US10520512B2/en active Active
-
2019
- 2019-12-18 US US16/719,507 patent/US20200326350A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10520512B2 (en) | 2019-12-31 |
TR201811201T4 (tr) | 2018-09-21 |
US20200326350A1 (en) | 2020-10-15 |
CN103308670A (zh) | 2013-09-18 |
CN103308670B (zh) | 2017-06-09 |
EP2823316B1 (en) | 2018-05-23 |
WO2013132090A1 (en) | 2013-09-12 |
US20150056203A1 (en) | 2015-02-26 |
EP2823316A1 (en) | 2015-01-14 |
JP2015512048A (ja) | 2015-04-23 |
RU2685713C2 (ru) | 2019-04-23 |
RU2014140427A (ru) | 2016-04-27 |
JP6262669B2 (ja) | 2018-01-17 |
ES2684512T3 (es) | 2018-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01937A (tr) | ||
MX2016002987A (es) | Biomarcadores de expresion de genes con sensibilidad a laquinimod. | |
WO2013159872A8 (en) | Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope | |
WO2013084002A3 (en) | Method for detecting nucleosome adducts | |
EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
BR112013000760A2 (pt) | método e aparelho para medir a espessura do tecido adiposo | |
NZ601590A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
MX364410B (es) | Metodo para detectar nucleosomas que contienen nucleotidos. | |
WO2013175314A3 (en) | System and method for detecting preeclampsia | |
WO2010148391A3 (en) | Biomarker assay of neurological condition | |
NZ630421A (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
WO2013067495A3 (en) | Personal spirometer | |
BR112015003046A2 (pt) | sistema de neurofeedback, processador de sinal para determinação de uma característica do sinal do sinal do biofeedback medido, método para provisão de um usuário com o neurofeedback e programa de computador. | |
WO2010041046A8 (en) | Granin proteins as markers of heart disease | |
WO2014053466A3 (en) | System and method for assessing risk associated with a glucose state | |
WO2012078623A3 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
MX2021012347A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
BR112014009223A2 (pt) | método para o diagnóstico da doença de niemann-pick | |
IN2014MN01940A (tr) | ||
NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
BR112015014232A2 (pt) | lesão renal aguda | |
WO2014187884A3 (en) | Mirnas as non-invasive biomarkers for heart failure | |
WO2011085057A3 (en) | Methods for detecting insulin autoantibody | |
WO2015192854A3 (en) | Methods and tools for predicting steatohepatitis | |
RU2010145662A (ru) | Способ прогнозирования риска смерти больных хронической сердечной недостаточностью |